StockData

Akebia Therapeutics vs Kamada

AKBA and KMDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

akbaAkebia Therapeutics$0.47−74.4% in 1 yearkmdaKamada$8.09+11.1% in 1 year

How AKBA and KMDA compare

Kamada grew revenue faster over the last twelve months (13.2% versus −12.4% for Akebia Therapeutics).

Kamada scores higher on the StockData Score (5 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAKBAKMDA
Size and price
Market cap$131M–
Share price$0.474$8.09
Change, 1 year−74.4%11.1%
Change, 5 years−82.9%44.5%
Beta (5Y)1.100.76
Employees194393
StockData Score
Total score45 (better)
Valuation score00
Growth score02 (better)
Performance score2 (better)0
Health score23 (better)
Dividend score00
Valuation
P/S0.7×–
P/B6.5×–
P/FCF9.5×–
FCF yield10.5%–
Growth
Revenue growth (TTM)−12.4%13.2% (better)
Revenue growth, 5Y average−4.3%6.3% (better)
EPS growth, 5Y average–−1.6%
Profitability
Gross margin78.9% (better)40.8%
Operating margin−15.7%14.5% (better)
Net margin−22.6%–
FCF margin7.0%–
Return on equity−144%–
Financial health
Debt / equity2.47–
Net debt / EBITDA–−0.54
Interest coverage–26.8×
Current ratio1.364.06 (better)
Altman Z-score−6.30–
Piotroski F-score7–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions39.7%8.6%
Held by insiders2.9%45.3%
Insider net buying, 12 months−$876K (better)−$1.7M
Short interest, % of float10.1%0.53%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.